Researchers compared plaque-forming and wild-type mice at six and 18 months, using EEG and muscle recordings to distinguish sleep stages and light-sheet microscopy to examine amyloid plaques and microglia, so normal aging and plaque pathology were compared rather than treated as one process. [1]

After 14 days of pexidartinib, about 87 percent of the brain's microglia were temporarily removed, and the plaque-model mice gained more than two hours of sleep a day, particularly non-rapid-eye-movement sleep. [1]

The amyloid-plaque burden did not change during the intervention, but that result shows only that sleep improved without plaque removal in this experiment; it does not refute amyloid's role, demonstrate better cognition or establish slower disease progression, and sleep loss had not worsened in step with the larger plaque burden at 18 months.

ScienceDaily calls the work a breakthrough, yet the tested population was mice and the intervention depleted most of their brain immune cells with a drug developed for cancer research, while the release gives no group sizes or full adverse-outcome record and supplies no human efficacy or safety evidence.

The experiment identifies microglial activity as a research target for sleep disruption in this model, not a treatment recommendation: any translational claim would require a safer way to alter the pathway, replicated animal work and human studies measuring sleep, cognition, progression and harms rather than assuming that more sleep changes memory or daily function.

-- KENJI NAKAMURA, Tokyo